21st North

ULGX · OTC

$0.00+$0.0001 (−100.00%)TodayMarket closed ·
No price history for this range.

About ULGX

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia. The company is headquartered in Minneapolis, Minnesota and currently employs 61 full-time employees. The firm is engaged in providing a range of services and project management for the mineral industry. The company offers its clients multidisciplinary solutions combining geological knowledge with the latest exploration tools. Its services include office services and data management, and contract exploration. Its office services and data management services include property appraisal and independent valuations, report writing and resource compilations, exploration strategy, target generation and development, and outlining and supervision of metallurgical test work programs. Its contract exploration services include geological prospecting, exploration and mapping, project management / site management and geological staffing, and supervision and management of ground/airborne geophysical surveys.

Employees
61
Headquarters
Minneapolis, Minnesota
Listed
May 30, 1996
Sector
Health Care
Industry
Health Care Equipment & Supplies

ULGX key statistics

Market cap
22
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.00K
Volume
60
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.015
52 Week low
$0.00

21st North (ULGX) at a glance

As of Oct 14, 2026, 21st North (ULGX) shares are priced at $0.00, giving the company a market cap of 22 and a price-to-earnings ratio of 0.00.

Volume so far is 60 shares, below the average of 1.00K shares a day.

Over the past year 21st North has ranged from $0.00 to $0.015, and now sits 0% of the way up that range.

21st North met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY13 it reported -$0.06 per share against an estimate of -$0.0612.

ULGX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 9.3% on average.

  1. Q4 FY10: reported -$0.04 per share against an estimate of -$0.0306
  2. Q1 FY11: reported -$0.05 per share against an estimate of -$0.0816
  3. Q2 FY11: reported -$0.05 per share against an estimate of -$0.051
  4. Q3 FY11: reported -$0.07 per share against an estimate of -$0.0612
  5. Q4 FY12: reported -$0.08 per share against an estimate of -$0.0612
  6. Q1 FY13: reported -$0.06 per share against an estimate of -$0.0612
  7. Q2 FY13: reported -$0.05 per share against an estimate of -$0.051
  8. Q3 FY13: reported -$0.06 per share against an estimate of -$0.0612

Similar companies

Companies in the same industry as 21st North

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.